Compare
Biofrontera Inc. vs Xilio Therapeutics, Inc. vs Integrated Biopharma Inc vs Cumberland Pharmaceuticals Inc
| Latest fiscal year | Biofrontera Inc. BFRI | Xilio Therapeutics, Inc. XLO | Integrated Biopharma Inc INBP | Cumberland Pharmaceuticals Inc CPIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $41.70M | $43.77M | $43.87M | $44.52M |
| Revenue growth (YoY) | +11.7% | +589.9% | -19.3% | +17.6% |
| Gross margin | n/a | n/a | 1.8% | 85.0% (computed) |
| Operating margin | -27.2% | -95.9% | -6.2% | -6.3% |
| Net margin | -25.3% | -80.1% | -6.5% | -6.4% |
| Net income | -$10.54M | -$35.04M | -$2.84M | -$2.84M |
| EPS (Diluted) | -$1.04 | -$4.19 | -$0.09 | -$0.19 |
| Operating cash flow | -$13.36M | -$4.99M | $1.24M | $4.93M |
| Free cash flow | -$13.36M | -$5.51M | $895.0K | $4.83M |
| Cash & equivalents | $6.39M | $137.53M | $4.47M | $11.44M |
| Total assets | $28.56M | $154.69M | $25.34M | $76.82M |
| Total liabilities | $18.08M | $119.41M | $7.67M | $52.28M |
| Shareholders' equity | $10.48M | $35.27M | $17.67M | $24.88M |
| Return on year-end equity | -100.5% | -99.3% | -16.1% | -11.4% |
| Shares outstanding | 11.65M | 4.53M | 31.06M | 14.96M |
Revenue, most recent five fiscal years
| Fiscal year | Biofrontera Inc. | Xilio Therapeutics, Inc. | Integrated Biopharma Inc | Cumberland Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $41.70M Ended 2025-12-31 | $43.77M Ended 2025-12-31 | $43.87M Ended 2026-06-30 | $44.52M Ended 2025-12-31 |
| 1 year earlier | $37.32M Ended 2024-12-31 | $6.34M Ended 2024-12-31 | $54.35M Ended 2025-06-30 | $37.87M Ended 2024-12-31 |
| 2 years earlier | $34.07M Ended 2023-12-31 | n/a | $50.32M Ended 2024-06-30 | $39.55M Ended 2023-12-31 |
| 3 years earlier | $28.67M Ended 2022-12-31 | n/a | $50.67M Ended 2023-06-30 | $42.01M Ended 2022-12-31 |
| 4 years earlier | $24.10M Ended 2021-12-31 | n/a | $56.25M Ended 2022-06-30 | $35.05M Ended 2021-12-31 |